期刊:Pharmacopsychiatry [Thieme Medical Publishers (Germany)] 日期:2016-05-10卷期号:49 (03)
标识
DOI:10.1055/s-0036-1582020
摘要
In psychiatry, therapeutic drug monitoring (TDM) is established to improve the efficacy and safety of pharmacotherapies. Since potential benefits of TDM for optimization of pharmacotherapy can only be reaped if the method is adequately integrated into the clinical treatment process and current TDM use in psychiatric and neurologic care is far from optimal, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP e.V.) issued consensus guidelines for best practice of TDM in psychiatry. A first version was published in 2004. These guidelines were extended in 2011, and an update is actually in preparation. The aim of this presentation is to explain the best practice of TDM in psychiatry in accordance with the updated consensus guidelines. Typical indications for TDM are suspected non-adherence, lack of clinical improvement under recommended doses or drug-drug interactions. When adverse effects are associated with clinical improvement under recommended doses, TDM may clarify if side effects are related to excessively high drug levels in the blood and if the dose can be decreased without loss of efficacy. Interpretation of laboratory results is always an essential part of TDM. In the new AGNP TDM guideline updated dose related and therapeutic reference ranges are now given for more than 130 neuropsychiatric drugs. Moreover, recommendations are given how to combine TDM with pharmacogenetic tests. Using TDM in accordance with the updated AGNP consensus guidelines enables rational clinical decision making for pharmacotherapy in psychiatry.